235 filings
Page 2 of 12
8-K
nfg66 x7w
28 Jun 22
Departure of Directors or Certain Officers
9:46am
8-K
glk qdfweu4va1jzg
27 Jun 22
Submission of Matters to a Vote of Security Holders
6:05am
8-K
8mspcd 3hzafi3c9w87h
6 Jun 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:16pm
8-K
5gair9w0p8ig2wv5 rn
27 May 22
Regulation FD Disclosure
8:44am
8-K
a9r9igcnq38rraf
12 Jan 22
Hepion Pharmaceuticals Announces Death of Director, Thomas Adams
10:08am
8-K
iiurui xu
10 Jan 22
Regulation FD Disclosure
6:02am
8-K
obef gvjvw
6 Jan 22
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
5:18pm
8-K
a6xi8dapivd yb
21 Dec 21
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
8:25am
8-K
dcyh1w18
30 Nov 21
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
8:10am
8-K
8nnfdi8 vxhc
16 Nov 21
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
8:53am
8-K
pucl4ne
10 Nov 21
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
9:41am
8-K
4hirm1f k2poricdg4z
8 Oct 21
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
to285ruxkgdblz5cgxv
7 Oct 21
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
4:24pm
8-K
277eglt4lbrss21mjyx2
30 Sep 21
A BETTER APPROACH TO DRUG DEVELOPMENT FOR LIVER DISEASES October 202 1 | INVESTOR PRESENTATION smart drug smart technology smart development
5:22pm
8-K
n0cv59at3jju
29 Sep 21
Other Events
9:22am
8-K
aevctz jj
13 Sep 21
Regulation FD Disclosure
8:28am
8-K
wvr7td64ds6l59djc
23 Aug 21
Amendments to Articles of Incorporation or Bylaws
9:19am
8-K
h2y3058ie
26 Jul 21
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
12:00am
8-K
4fyu kuzid
13 Jul 21
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
10:38am
8-K
3p65b2ecb6 6jehcgu2
25 Jun 21
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
4:46pm